In-Depth Study on Telomerase Reverse Transcriptase - Pipeline Review, H1 2016

Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) - Pipeline Review, H1 2016 ​is a new market research publication announced by Reportstack. This report provides in depth analysis on Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) targeted pipeline therapeutics.

The report provides comprehensive information on the Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) targeted therapeutics development and features dormant and discontinued projects.

To access full report with TOC, please visit Telomerase Reverse Transcriptase - Pipeline Review, H1 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape for Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49)
- The report reviews Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report reviews latest news and deals related to Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) targeted therapeutics

Reasons to buy

- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned

Adamis Pharmaceuticals Corporation Argos Therapeutics, Inc. Asterias Biotherapeutics, Inc. e-Therapeutics Plc F. Hoffmann-La Roche Ltd. Inovio Pharmaceuticals, Inc. Invectys SA Johnson & Johnson Komipharm International Co., Ltd. Mediolanum farmaceutici S.p.A. Ultimovacs AS Vaxon Biotech

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###